Drug interactions: Proteins, pumps, and P-450s

被引:58
作者
Shapiro, LE
Shear, NH
机构
[1] Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Clin Pharmacol, Toronto, ON M4N 3M5, Canada
[2] Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Dermatol, Toronto, ON M4N 3M5, Canada
[3] Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Med, Drug Safety Clin, Toronto, ON M4N 3M5, Canada
[4] Univ Toronto, Toronto, ON, Canada
关键词
D O I
10.1067/mjd.2002.126823
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
The two major concerns. in drug safety are adverse drug reactions and drug interactions. When multiple drug therapies are prescribed, drug interactions become an important consideration for patients and physicians. The life of a drug is reviewed with emphasis on absorption, distribution, metabolism, and excretion. Pharmacokinetic and pharmacodynamic mechanisms for drug interactions are reviewed. The contributions of P-glycoprotein, pharmacogenetic variation, and genetic polymorphisms to drug interactions are highlighted. Prediction of drug interactions is possible with knowledge of which agents are likely to cause alterations in drug metabolism.
引用
收藏
页码:467 / 484
页数:18
相关论文
共 92 条
[11]   IN-VITRO APPROACHES CAN PREDICT HUMAN DRUG-METABOLISM [J].
BIRKETT, DJ ;
MACKENZIE, PI ;
VERONESE, ME ;
MINERS, JO .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1993, 14 (08) :292-294
[12]  
Boberg M, 1997, DRUG METAB DISPOS, V25, P321
[13]  
BODEY GP, 1992, CLIN INFECT DIS, V14, P5161
[14]   Quantitative drug interactions prediction system (Q-DIPS) -: A dynamic computer-based method to assist in the choice of clinically relevant in vivo studies [J].
Bonnabry, P ;
Sievering, J ;
Leemann, T ;
Dayer, P .
CLINICAL PHARMACOKINETICS, 2001, 40 (09) :631-640
[15]   Distinct drug-interaction profiles for statins [J].
Bottorf, MB .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1999, 56 (10) :1019-1020
[16]  
Burkhart CN, 2000, VET HUM TOXICOL, V42, P30
[17]   DETERMINATION OF CYP1A2 AND NAT2 PHENOTYPES IN HUMAN-POPULATIONS BY ANALYSIS OF CAFFEINE URINARY METABOLITES [J].
BUTLER, MA ;
LANG, NP ;
YOUNG, JF ;
CAPORASO, NE ;
VINEIS, P ;
HAYES, RB ;
TEITEL, CH ;
MASSENGILL, JP ;
LAWSEN, MF ;
KADLUBAR, FF .
PHARMACOGENETICS, 1992, 2 (03) :116-127
[18]  
CANTILENA LR, 1995, CLIN PHARMACOL THER, V57, P185
[19]   St John's wort interaction with digoxin [J].
Cheng, TO .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (16) :2548-2548
[20]  
DALY AK, 1995, J MOL MED-JMM, V73, P539